Foundation for the National Institutes of Health

NIH Awards Amulet SBIR Grant for Consumer Gluten Sensor

Retrieved on: 
Monday, August 7, 2023
Food, Fatigue, Amulet, SBIR, Myalgia, Small Business Innovation Research, Food safety, Triticale, Human, Ataxia, Constipation, Brain, Dartmouth College, Gluten-related disorders, Foundation for the National Institutes of Health, Asthma, Plant, Chemistry, Pesticide, Wheat allergy, Iron deficiency, Patient, Dermatitis herpetiformis, Restaurant, Joint, Bloating, Immunology, Health, FDA, NIH, Skin, Migraine, Flour, Pharmaceutical industry

MADISON, Wis., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Amulet, maker of the world's smallest, fastest, and portable electrochemical food sensor, announced today the receipt of a National Institute of Health (NIH) Small Business Innovative Research (SBIR) grant for detecting gluten in food.

Key Points: 
  • A rapid, field-portable consumer sensor for detecting gluten in food.
  • MADISON, Wis., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Amulet , maker of the world's smallest, fastest, and portable electrochemical food sensor, announced today the receipt of a National Institute of Health (NIH) Small Business Innovative Research (SBIR) grant for detecting gluten in food.
  • They include wheat allergy, gluten ataxia, dermatitis herpetiformis, non-celiac gluten sensitivity and celiac disease—an autoimmune disease in which the immune system reactions abnormally to gluten, causing damage to the lining of the small intestine.
  • Our goal at Amulet is to provide consumers with a tool to help them avoid gluten, and in turn, better manage their health," says Amulet Co-Founder & CEO, Abigail Barnes.

Feinstein Institutes’ Dr. Ping Wang Receives 2023 Mentor Award From the Shock Society

Retrieved on: 
Tuesday, July 25, 2023
Health, Neurology, Clinical Trials, Research, Science, Biotechnology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Donald, Hofstra University, Feinstein Institutes for Medical Research, Injury, Organ dysfunction, Multimedia, Mentorship, Cell, Doctor of Philosophy, Bangladesh Technical Education Board, Death, Publication, MD, Immune system, DSM-IV codes, Bacteria, Medical research, Trauma, Credit, Conference, Radiation exposure, Foundation for the National Institutes of Health, Inflammation, Pharmaceutical industry, Nursing, Management, Shock, Sepsis

Ping Wang, MD , an investigator at The Feinstein Institutes for Medical Research, has dedicated his career to sepsis research and is being rewarded with the Shock Society Mentor Award for his leadership and mentoring of young clinicians and basic researchers at the US Shock Society’s 46th annual Conference on Shock last month in Portland, OR.

Key Points: 
  • Ping Wang, MD , an investigator at The Feinstein Institutes for Medical Research, has dedicated his career to sepsis research and is being rewarded with the Shock Society Mentor Award for his leadership and mentoring of young clinicians and basic researchers at the US Shock Society’s 46th annual Conference on Shock last month in Portland, OR.
  • View the full release here: https://www.businesswire.com/news/home/20230725035596/en/
    Dr. Ping Wang was recently awarded with the Shock Society’s Mentor Award for his leadership and mentorship.
  • (Credit: Feinstein Institutes)
    The Shock Society Mentor Award annually honors a member of the Shock Society for excellence in mentoring trainees and junior faculty.
  • He served as president of the Shock Society from 2016-2017 and was program chair at the 2013 Conference on Shock.

OATS from AARP works with T-Mobile to Empower Older Adults Across the South with Skills to Leverage Today's Newest Technology

Retrieved on: 
Tuesday, July 18, 2023
Digital divide, OATS, Senior, AARP, Internet, Government, T-Mobile, SVP, Nationwide, Boy, County, Foundation for the National Institutes of Health, Nursing, Toy

NEW YORK, July 18, 2023 /PRNewswire/ -- Nationwide - To expand access to essential tech training for older adults throughout rural southern communities, Older Adults Technology Services (OATS) from AARP is working with T-Mobile to equip seniors with the tools and knowledge to thrive in the digital age. The initiative will leverage Senior Planet from AARP, the flagship program of OATS, to bolster a network of senior-serving organizations with age-relevant technology training programs.

Key Points: 
  • OATS will support 100 community partners who collectively serve over 4,300 older adults across multiple southern rural counties.
  • The initiative will leverage Senior Planet from AARP, the flagship program of OATS, to bolster a network of senior-serving organizations with age-relevant technology training programs.
  • "We are thrilled to work with Older Adults Technology Services from AARP to provide seniors with the digital literacy skills training they need to stay connected and thrive in the digital world."
  • It comes at a time when millions of American seniors lack the digital literacy skills to feel confident utilizing modern technology.

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, Penta, Unitaid, Monell Chemical Senses Center, Emtricitabine, Gilead Sciences, CHAI, Partnership, Sofosbuvir, Prevalence, HIV, European and Developing Countries Clinical Trials Partnership, Bill & Melinda Gates Foundation, TAF, SOF, DBM, Global health, Research, Medicine, Doctor of Philosophy, Bangladesh Technical Education Board, UNIVERSAL, EDCTP, Foundation for the National Institutes of Health, MD, Patient, Child, Viral, Developing country, Science, Mortality, Pediatrics, Technology transfer, Caregiver, Pharmaceutical industry, Vaccine

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.

Key Points: 
  • For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
  • However, just over 50% of them are on antiretroviral treatment compared to 76% of adults living with HIV on treatment today.
  • Many LMICs have a high burden of mother-to-child transmission and the prevalence of HIV among children remains high.
  • “By developing medicine formulations that meet the needs of children, and by improving palatability, through these partnership, we have the ability to potentially increase adherence rates in children.

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

Retrieved on: 
Wednesday, July 12, 2023
Heart, Obesity, Drug development, Diet, Rejuvenation, Apolipoprotein E, Prevalence, Life, Diabetes, Inflammaging, Albert Einstein's brain, Overalls, DSM-IV codes, Quality of life, Cross, Brain, Research, Inflammation, Biomarker, Autoimmunity, Trial of the century, Cellular senescence, Literature, Pesticide, Aging brain, MD, Patient, Tesi, Conditional sentence, Health, AD, Smoking, Conference, Foundation for the National Institutes of Health, Neuroinflammation, Disease, Medical imaging, Ageing

Boca Raton, Florida, July 12, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023.

Key Points: 
  • Chronic diseases of aging affect virtually every organ system, including the heart, brain, eyes, ears, bones, and skeletal muscles.
  • Unfortunately, they contribute to a diminished health span, resulting in shortened life spans, increased elder care costs, and reduced quality of life.
  • “Cognitive aging is a well-defined disease that has not been the subject of extensive clinical study or intervention,” said CJ Barnum, VP CNS Development at INmune Bio.
  • Unfortunately, no treatments currently exist for inflammaging.”
    “The field of aging research and drug development has many challenges,” said RJ Tesi, MD, CEO of INmune Bio said.

UT System Regents Invest in New Student Mental Health Resources

Retrieved on: 
Tuesday, June 20, 2023
UT System, Partnership, UT, Education, Research, Connecticut Board of Regents for Higher Education, Student, Gallup, Mental, University of Texas at Austin, Health, Lumina Foundation, Mental health, NIH, Foundation for the National Institutes of Health, Safety, Nursing

This partnership is one component of a $16.5 million investment by the UT Board of Regents last year to expand and enhance student mental health and safety, as well as other alcohol and drug education resources at all  UT academic and health institutions.

Key Points: 
  • This partnership is one component of a $16.5 million investment by the UT Board of Regents last year to expand and enhance student mental health and safety, as well as other alcohol and drug education resources at all  UT academic and health institutions.
  • In 2011, the UT System became the first system of higher education in the nation to invest in comprehensive alcohol prevention, education, and recovery programs at each of its academic campuses.
  • "We know that students' mental health is tied to their academic achievement and that the demand for access to mental health services for UT students has never been greater," said UT System Chancellor James B. Milliken.
  • We are proud that this latest investment will make mental health resources more readily available and easier to access for UT students."

Groundbreaking Nonprofit, CureALS Founded and Launched by Former NCR Chairman and CEO Bill Nuti to Eradicate ALS

Retrieved on: 
Friday, June 2, 2023
Health Technology, Data Management, Start-Up, Other Health, Technology, Professional Services, Mental Health, Philanthropy, Neurology, Artificial Intelligence, Fund Raising, Foundation, Science, Other Philanthropy, Research, Health, Frontotemporal dementia, LLM, Number Four, Partnership, Cisco, Ice Bucket Challenge, Alzheimer's disease, Survival, ALS, Hope, History, NCR, Government, Bill Nuti, Data science, Parkinson's disease, Patient, Amyotrophy, Biology, Artificial intelligence, Diagnosis, Hospital, AI, Fluid mechanics, NIH, Foundation for the National Institutes of Health, Disease, Management, Pharmaceutical industry, Medical device, Caterpillar

CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched today.

Key Points: 
  • CureALS, a pioneering nonprofit organization dedicated to eliminating ALS (Amyotrophic Lateral Sclerosis) and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched today.
  • In addition, the number of ALS cases worldwide is projected to soar from 223,000 in 2015 to a staggering 377,000 in 2040, representing an increase of 69%.
  • In the words of one of the foremost neurologists and ALS researchers, Dr.
  • In 2014 the Ice Bucket Challenge raised an impressive $115 million for ALS research and sparked widespread public awareness.

Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, April 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, JDRF, Angeles volunteer association, University of Colorado School of Medicine, Drug development, University, National Jewish Health, T1D, Pediatrics, University of California, San Francisco, INVU (album), Rheumatology, CMO, Multiple sclerosis, Biomarker, Bangladesh Technical Education Board, TCR, Merck & Co., Foundation for the National Institutes of Health, MS, Science, Regulatory T cell, Third Rock Ventures, Patient, UCSF, Autoimmune disease, Lightspeed Venture Partners, Biology, Knowledge, Therapy, IND, Autoimmunity, Inflammation, Pharmaceutical industry, Nursing, Genentech

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Key Points: 
  • Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.
  • Dr. Dragone brings to Abata extensive experience in preclinical and early clinical development and autoimmune medicine.
  • I’m thrilled he’ll be joining us to advance this work.”
    Dr. Dragone most recently served as chief medical officer at Sonoma Biotherapeutics.
  • Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases.

DMI AWARDED RECOMPETE CONTRACT WITH NATIONAL INSTITUTE OF HEALTH

Retrieved on: 
Wednesday, April 19, 2023
ICS, DMI, Public sector, Bangladesh Technical Education Board, OIT, Health, Foundation for the National Institutes of Health, Information technology, NIH, Risk management

BETHESDA, Md., April 19, 2023 /PRNewswire/ -- DMI, a global leader in digital transformation and IT managed services, announced today that it has been awarded the recompete for the Cybersecurity Modernization II Initiative for The National Institutes of Health (NIH) Office of Director (OD) Office of Information Technology (OIT) contract. Worth $24 million over three years, the win will build on DMI's two previous contracts with the NIH OD to provide cybersecurity modernization services. 

Key Points: 
  • BETHESDA, Md., April 19, 2023 /PRNewswire/ -- DMI , a global leader in digital transformation and IT managed services, announced today that it has been awarded the recompete for the Cybersecurity Modernization II Initiative for The National Institutes of Health (NIH) Office of Director (OD) Office of Information Technology (OIT) contract.
  • Worth $24 million over three years, the win will build on DMI's two previous contracts with the NIH OD to provide cybersecurity modernization services.
  • "This win validates the National Institute of Health's confidence in DMI's capacity to deliver high-quality, strategic cybersecurity services," said Rocky Thurston, chief operating officer, DMI.
  • The National Institute of Health is the nation's core medical research agency and has paved the way for key medical discoveries to improve the health of the United States' population.

BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes

Retrieved on: 
Thursday, April 13, 2023
Gelsolin, Infection, NORTH, Hyperglycemia, Type 2 diabetes, University, Diabetes, Neutrophil, NLRP3, Woman, Intramural sports, Journal of Translational Medicine, Inflammation, Bangladesh Technical Education Board, Maryland School, University of Maryland School of Medicine, Ageing, US, MP, Oxidative stress, Type, Saipan, Journal, Translational medicine, Patient, Mouse, Therapy, White, Foundation for the National Institutes of Health, NIH Intramural Research Program, Pharmaceutical industry, Dietary supplement, Vaccine, Poverty

NORTH BRUNSWICK, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN), a highly conserved and abundant endogenous human immune regulatory protein, announces publication of two new research studies exploring gelsolin’s role in type 2 diabetes, an inflammation-related metabolic disease.

Key Points: 
  • Low levels of gelsolin identified in individuals with type 2 diabetes living below poverty.
  • It explored the role of microparticles (MPs) which drive inflammation in individuals with diabetes.
  • Type 2 diabetic subjects with foot ulcers were shown to have up to 14-fold elevations of blood-borne F-actin-coated microparticles.
  • White adults with diabetes had lower levels compared to White adults without diabetes and to African American individuals either with or without diabetes.